This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cianfrocca, M. Articles by Dezube, B. J. Search for Related Content PubMed PubMed Citation Articles by Cianfrocca, M. Articles by Dezube, B. J. Social Bookmarking                            What's this?

Matrix Metalloproteinase Inhibitor COL-3 in the Treatment of AIDS-Related Kaposi’s Sarcoma: A Phase I AIDS Malignancy Consortium Study

From the Beth Israel Deaconess Medical Center; Boston Medical Center; and Massachusetts General Hospital, Boston, MA; Northwestern University, Chicago, IL; Washington University, St Louis, MO; Memorial Sloan-Kettering Cancer Center, New York, NY; Clinical Pharmacokinetics Section and Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD; and AIDS Malignancy Consortium Operations Center, University of Alabama at Birmingham, Birmingham, AL.

Address reprint requests to Bruce Dezube, MD, Beth Israel Deaconess Medical Center, 330 Brookline Ave, CC-913, Boston, MA 02215; email: bdezube{at}caregroup.harvard.edu

PURPOSE: Matrix metalloproteinases (MMPs) are involved in tumor invasion and metastasis and are overexpressed in Kaposi’s sarcoma (KS) cells. The primary aim was to define the safety and toxicity of the MMP inhibitor COL-3 in patients with AIDS-related KS. Secondary aims were to evaluate tumor response, pharmacokinetics, and changes in blood levels of MMP-2, MMP-9, vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF).

PATIENTS AND METHODS: COL-3 was administered orally once daily, and doses were escalated in cohorts of three to six subjects. Patients with symptomatic visceral KS or severe tumor-associated edema were excluded. Antiretroviral therapy was permitted but not required. Study end points were grade 3 or 4 toxicity or progressive KS. Serial blood specimens were obtained for pharmacokinetics and levels of MMP-2, MMP-9, VEGF, and bFGF.

RESULTS: Eighteen patients received COL-3 in dosing cohorts of 25, 50, and 70 mg/m²/d. Prior KS therapy was reported by 17 patients (94%). COL-3–related grade 3 or 4 adverse events were reported by six patients and included photosensitivity, rash, and headache. There was one complete response and seven partial responses, for an overall response rate of 44%, with a median response duration of 25+ weeks. The median COL-3 half-life was 39.3 hours (range, 4.1 to 251.1 hours). There was a significant difference between responders and nonresponders with respect to the change in MMP-2 serum levels from baseline to minimum value on treatment (P = .037).

CONCLUSION: COL-3 administered orally once daily to patients with AIDS-related KS is reasonably well tolerated. The most common adverse event was dose-related photosensitivity. Antitumor activity was noted. Further evaluation of COL-3 for the treatment of KS is warranted.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				L. Lin, J. Y. Lee, L. D. Kaplan, B. J. Dezube, A. Noy, S. E. Krown, A. M. Levine, Y. Yu, G. S. Hayward, and R. F. Ambinder Effects of Chemotherapy in AIDS-Associated Non-Hodgkin's Lymphoma on Kaposi's Sarcoma Herpesvirus DNA in Blood J. Clin. Oncol., May 20, 2009; 27(15): 2496 - 2502. [Abstract] [Full Text] [PDF]

				P. P. Rose, M. Bogyo, A. V. Moses, and K. Fruh Insulin-Like Growth Factor II Receptor-Mediated Intracellular Retention of Cathepsin B Is Essential for Transformation of Endothelial Cells by Kaposi's Sarcoma-Associated Herpesvirus J. Virol., August 1, 2007; 81(15): 8050 - 8062. [Abstract] [Full Text] [PDF]

				L.-W. Qian, J. Xie, F. Ye, and S.-J. Gao Kaposi's Sarcoma-Associated Herpesvirus Infection Promotes Invasion of Primary Human Umbilical Vein Endothelial Cells by Inducing Matrix Metalloproteinases J. Virol., July 1, 2007; 81(13): 7001 - 7010. [Abstract] [Full Text] [PDF]

				N. L. Webster and S. M. Crowe Matrix metalloproteinases, their production by monocytes and macrophages and their potential role in HIV-related diseases J. Leukoc. Biol., November 1, 2006; 80(5): 1052 - 1066. [Abstract] [Full Text] [PDF]

				M. Stefanidakis and E. Koivunen Cell-surface association between matrix metalloproteinases and integrins: role of the complexes in leukocyte migration and cancer progression Blood, September 1, 2006; 108(5): 1441 - 1450. [Abstract] [Full Text] [PDF]

				B. J. Dezube, S. E. Krown, J. Y. Lee, K. S. Bauer, and D. M. Aboulafia Randomized Phase II Trial of Matrix Metalloproteinase Inhibitor COL-3 in AIDS-Related Kaposi's Sarcoma: An AIDS Malignancy Consortium Study J. Clin. Oncol., March 20, 2006; 24(9): 1389 - 1394. [Abstract] [Full Text] [PDF]

				J. T. Peterson The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors Cardiovasc Res, February 15, 2006; 69(3): 677 - 687. [Abstract] [Full Text] [PDF]

				S. S. Kocer, S. G. Walker, B. Zerler, L. M. Golub, and S. R. Simon Metalloproteinase Inhibitors, Nonantimicrobial Chemically Modified Tetracyclines, and Ilomastat Block Bacillus anthracis Lethal Factor Activity in Viable Cells Infect. Immun., November 1, 2005; 73(11): 7548 - 7557. [Abstract] [Full Text] [PDF]

				A. Kaliski, L. Maggiorella, K. A. Cengel, D. Mathe, V. Rouffiac, P. Opolon, N. Lassau, J. Bourhis, and E. Deutsch Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion Mol. Cancer Ther., November 1, 2005; 4(11): 1717 - 1728. [Abstract] [Full Text] [PDF]

				E. Rosenbaum, M. Zahurak, V. Sinibaldi, M. A. Carducci, R. Pili, M. Laufer, T. L. DeWeese, and M. A. Eisenberger Marimastat in the Treatment of Patients with Biochemically Relapsed Prostate Cancer: A Prospective Randomized, Double-Blind, Phase I/II Trial Clin. Cancer Res., June 15, 2005; 11(12): 4437 - 4443. [Abstract] [Full Text] [PDF]

				M. C. Cheung, L. Pantanowitz, and B. J. Dezube AIDS-Related Malignancies: Emerging Challenges in the Era of Highly Active Antiretroviral Therapy Oncologist, June 1, 2005; 10(6): 412 - 426. [Abstract] [Full Text] [PDF]

				B. Fingleton, R. Menon, K. J. Carter, P. D. Overstreet, D. L. Hachey, L. M. Matrisian, and J. O. McIntyre Proteinase Activity in Human and Murine Saliva as a Biomarker for Proteinase Inhibitor Efficacy Clin. Cancer Res., December 1, 2004; 10(23): 7865 - 7874. [Abstract] [Full Text] [PDF]

				S. Syed, C. Takimoto, M. Hidalgo, J. Rizzo, J. G. Kuhn, L. A. Hammond, G. Schwartz, A. Tolcher, A. Patnaik, S. G. Eckhardt, et al. A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties Clin. Cancer Res., October 1, 2004; 10(19): 6512 - 6521. [Abstract] [Full Text] [PDF]

				C. Yang, M. Zeisberg, J. C. Lively, P. Nyberg, N. Afdhal, and R. Kalluri Integrin {alpha}1{beta}1 and {alpha}2{beta}1 Are the Key Regulators of Hepatocarcinoma Cell Invasion Across the Fibrotic Matrix Microenvironment Cancer Res., December 1, 2003; 63(23): 8312 - 8317. [Abstract] [Full Text] [PDF]

				M. A. Rudek, J. Venitz, Y. Ando, E. Reed, J. M. Pluda, and W. D. Figg Factors Involved in the Pharmacokinetics of COL-3, a Matrix Metalloproteinase Inhibitor, in Patients with Refractory Metastatic Cancer: Clinical and Experimental Studies J. Clin. Pharmacol., October 1, 2003; 43(10): 1124 - 1135. [Abstract] [Full Text] [PDF]

				F. A. Scappaticci Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies J. Clin. Oncol., September 15, 2002; 20(18): 3906 - 3927. [Abstract] [Full Text] [PDF]

				L. M. Coussens, B. Fingleton, and L. M. Matrisian Matrix Metalloproteinase Inhibitors and Cancer--Trials and Tribulations Science, March 29, 2002; 295(5564): 2387 - 2392. [Abstract] [Full Text] [PDF]